Biriketako minbiziaren tratamendua hainbat faktoreren araberakoa da, besteak beste, minbiziaren fasea, biriketako minbiziaren mota eta gaixoaren osasun orokorra.
Tratamendu-aukera ohikoen artean honako hauek daude:
1. Kirurgia: Sarritan, hau da tratamendu egokiena biriketako minbiziaren lehen fasean.
Zirujauak tumorea eta inguruko ehun osasungarriaren zati txiki bat kentzen ditu.
2. Erradiazio-terapia: Energia handiko erradiazioa erabiltzen da minbizi-zelulak hiltzeko eta tumoreak txikitzeko.
Bakarrik edo beste tratamendu batzuekin konbinatuta erabil daiteke.
3. Kimoterapia: tratamendu honetan, minbizi-zelulak hiltzeko botikak erabiltzen dira.
Zain barneko edo ahoz eman daiteke, eta askotan beste tratamendu batzuekin konbinatzen da.
4. Terapia bideratua: Tratamendu honek minbizi-zelulen hazkundeari eta biziraupenari laguntzen dieten gene edo proteina zehatzak bideratzen ditu.
Maiz erabiltzen da biriketako minbizi aurreratua edo metastatikoa tratatzeko.
5. Immunoterapia: Tratamendu honek sistema immunologikoak minbizi-zelulak antzematen eta erasotzen laguntzen du.
Maiz erabiltzen da biriketako minbizi aurreratua edo metastatikoa tratatzeko.
6. Terapia fotodinamikoa: Tratamendu honek argiak aktibatzen duen sendagai bat erabiltzen du minbizi-zelulak hiltzeko.
Maiz erabiltzen da biriketako minbiziaren lehen fasean.
7. Protonen terapia: Erradiazio-terapiaren mota bat da, zeinetan protonak erabiltzen baitira erradiografiaren ordez, tumoreari erradiazioa emateko.
Maiz erabiltzen da biriketako minbiziaren lehen fasean.
8. Azterketa klinikoak: Pazienteek tratamendu berriak edo tratamendu konbinazioak probatzen dituzten azterketa klinikoetan parte hartzeko eskubidea izan dezakete.
Garrantzitsua da tratamendu aukerarik onenak osasun-taldearekin eztabaidatzea, tratamendu plan eraginkorrena norberaren egoera espezifikoaren araberakoa izango baita.
Chen JH, Wu J, Xu Q: The emerging treatment landscape of targeted therapy in non-small-cell lung cancer. Signal Transduct Target Ther. , 4 (): 61.
Furuse K: [Photodynamic therapy of centrally located early-stage lung cancer]. Gan To Kagaku Ryoho. 1996, 23 (1): 27-30.
Gálffy G: [From rare mutations to classical ones, inhibition of signaling pathways in non-small cell lung cancer]. Magy Onkol. 2020, 64 (3): 196-204.
Magalhães M, Alvarez-Lorenzo C, Concheiro A, Figueiras A, Santos AC, Veiga F: RNAi-based therapeutics for lung cancer: biomarkers, microRNAs, and nanocarriers. Expert Opin Drug Deliv. 2018, 15 (10): 965-982.
Kataoka M, Fujiwara T, Tanaka N: [Gene therapy for lung cancer]. Nihon Geka Gakkai Zasshi. 2002, 103 (2): 244-9.
Jin C, Yang B: A Case of Delayed Diagnostic Pulmonary Tuberculosis during Targeted Therapy in an EGFR Mutant Non-Small Cell Lung Cancer Patient. Case Rep Oncol. , 14 (1): 659-663.
Wang Y, Liu Q, Chen H, You J, Peng B, Cao F, Zhang X, Chen Q, Uzan G, Xu L, Zhang D: Celastrol improves the therapeutic efficacy of EGFR-TKIs for non-small-cell lung cancer by overcoming EGFR T790M drug resistance. Anticancer Drugs. 2018, 29 (8): 748-755.
Erantzukizunik ez: medikoak.
Webgune hau hezkuntza eta informazio helburuetarako bakarrik eskaintzen da eta ez du aholkularitza medikoa edo zerbitzu profesionalik eskaintzen.
Ematen den informazioa ez da osasun-arazo edo gaixotasun bat diagnostikatzeko edo tratatzeko erabili behar, eta aholku mediko pertsonala bilatzen dutenek baimendutako mediku batekin kontsultatu behar dute.
Kontuan izan galderen erantzunak sortzen dituen sare neuronalak ez duela zehaztasunik, batez ere, eduki numerikoari dagokionez. Adibidez, gaixotasun jakin bat duten pertsonen kopurua.
Beti bilatu zure medikuaren aholkua edo beste osasun-zerbitzu kualifikatu bat gaixotasun mediko bati buruz. Sekula ez baztertu aholku mediko profesionala edo atzeratu webgune honetan irakurri duzun zerbaitengatik. Larrialdi mediko bat izan dezakezula uste baduzu, deitu 911 edo joan berehala larrialdietako gelara. Webgune honek edo haren erabilerak ez du mediku-paziente harremana sortzen. Ez BioMedLibek, ez bere langileek, ez webgune honetako inork ez du inolako adierazpenik egiten, espresorik edo inpliziturik, hemen emandako informazioari edo haren erabilerari dagokionez.
Arduragabekeria: egile eskubideak
1998ko Digital Millennium Copyright Act-ek, 17 U.S.C. § 512 (DMCA) -k, egile eskubideen jabeek Interneten agertzen den materialak AEBetako egile eskubideen arabera dituzten eskubideak urratzen dituela uste duten errekurtsoak eskaintzen ditu.
Fede onez uste baduzu gure webgunearekin edo zerbitzuekin lotuta eskuragarri dagoen eduki edo material batek zure egile eskubideak urratzen dituela, zuk (edo zure agenteak) jakinarazpen bat bidal diezagukezu eduki edo materiala kentzeko edo sarbidea blokeatzeko eskatuz.
Jakinarazpenak idatziz bidali behar dira posta elektronikoz (ikus "Kontaktua" atala posta elektronikoaren helbideari buruz).
DMCAk eskatzen du egile eskubideak urratzeari buruzko jakinarazpenean honako informazioa jasotzea: (1) urratzeari buruzko lanaren deskribapena; (2) urratzeari buruzko edukiaren deskribapena eta eduki hori aurkitzea ahalbidetzeko behar beste informazio; (3) zure harremanetarako informazioa, zure helbidea, telefono zenbakia eta posta elektronikoaren helbidea barne; (4) zure adierazpena, sinesmen ona duzula, salatutako moduan dagoen edukia ez dela egile eskubideen jabeak, edo bere agenteak, edo edozein legearen eraginez baimenduta.
(5) zure adierazpen bat, zin faltsuaren zigorraren pean sinatua, jakinarazpenean dagoen informazioa zehatza dela eta urratu direla dioten egile eskubideak betearazteko eskumena duzula;
eta (6) egile eskubideen jabearen edo egile eskubideen jabearen izenean jarduteko baimena duen pertsonaren sinadura fisikoa edo elektronikoa.
Goian aipatutako informazio guztia ez emateak zure kexaren tramitazioa atzeratzea ekar dezake.
Harremanetan jartzea
Bidali iezaguzu mezu elektroniko bat edozein galdera edo iradokizunekin.
How to treat lung cancer?
The treatment for lung cancer depends on several factors, including the stage of the cancer, the type of lung cancer, and the patient's overall health.
Some common treatment options include:
1. Surgery: This is often the preferred treatment for early-stage lung cancer.
The surgeon removes the tumor and a small portion of healthy tissue around it.
2. Radiation therapy: High-energy radiation is used to kill cancer cells and shrink tumors.
It can be used alone or in combination with other treatments.
3. Chemotherapy: This treatment uses drugs to kill cancer cells.
It can be given intravenously or or orally, and is often used in combination with other treatments.
4. Targeted therapy: This treatment targets specific genes or proteins that contribute to the growth and survival of cancer cells.
It is often used for advanced or metastatic lung cancer.
5. Immunotherapy: This treatment helps the immune system recognize and attack cancer cells.
It is often used for advanced or metastatic lung cancer.
6. Photodynamic therapy: This treatment uses a light-activated drug to kill cancer cells.
It is often used for early-stage lung cancer.
7. Proton therapy: This is a type of radiation therapy that uses protons instead of x-rays to deliver radiation to the tumor.
It is often used for early-stage lung cancer.
8. Clinical trials: Patients may be eligible to participate in clinical trials testing new treatments or combinations of treatments.
It is important to discuss the best treatment options with a healthcare team, as the most effective treatment plan will depend on the individual's specific situation.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
Gutxi gorabehera.
BioMedLib-ek ordenagailu automatikoak (makina-ikaskuntza algoritmoak) erabiltzen ditu galdera-erantzun bikoteak sortzeko.
35 milioi argitalpen biomediko PubMed/Medline-rekin hasten gara eta baita RefinedWeb-en web orrialdeekin ere.
Ikusi "Erreferentziak" eta "Erantzukizun-aitorpena".
